Cargando…

ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion

BACKGROUND: Previous studies suggested that the RhoA/ROCK pathway may contribute to vascular complications in diabetes. The present study was designed to investigate whether ROCK inhibitor fasudil could prevent high glucose-induced monocyte-endothelial cells adhesion, and whether this was related to...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hailing, Peng, Wenhui, Jian, Weixia, Li, Yuanmin, Li, Qi, Li, Weiming, Xu, Yawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461463/
https://www.ncbi.nlm.nih.gov/pubmed/22694757
http://dx.doi.org/10.1186/1475-2840-11-65
_version_ 1782245081535741952
author Li, Hailing
Peng, Wenhui
Jian, Weixia
Li, Yuanmin
Li, Qi
Li, Weiming
Xu, Yawei
author_facet Li, Hailing
Peng, Wenhui
Jian, Weixia
Li, Yuanmin
Li, Qi
Li, Weiming
Xu, Yawei
author_sort Li, Hailing
collection PubMed
description BACKGROUND: Previous studies suggested that the RhoA/ROCK pathway may contribute to vascular complications in diabetes. The present study was designed to investigate whether ROCK inhibitor fasudil could prevent high glucose-induced monocyte-endothelial cells adhesion, and whether this was related to fasudil effects on vascular endothelial cell expression of chemotactic factors, vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1). METHODS: HUVECs were stimulated with high glucose (HG) or HG + fasudil in different concentration or different time. Monocyte-endothelial cell adhesion was determined using fluorescence-labeled monocytes. The mRNA and protein expression of VCAM-1 and MCP-1 were measured using real-time PCR and western blot. The protein levels of RhoA, ROCKI and p-MYPT were determined using western blot analysis. ELISA was employed to measure the expression of soluble VCAM-1 and MCP-1 in cell supernatants and human serum samples. RESULTS: Fasudil significantly suppressed HG-induced adhesion of THP-1 to HUVECs. Fasudil reduced Rho/ROCK activity (as indicated by lower p-MYPT/MYPT ratio), and prevented HG induced increases in VCAM-1 and MCP-1 mRNA and protein levels. Fasudil also decreased MCP-1 concentration in HUVEC supernatants, but increased sVCAM-1 shedding into the media. In human diabetic subjects, 2 weeks of fasudil treatment significantly decreased serum MCP-1 level from 27.9 ± 10.6 pg/ml to 13.8 ± 7.0 pg/ml (P < 0.05), while sVCAM-1 increased from 23.2 ± 7.5 ng/ml to 39.7 ± 5.6 ng/ml after fasudil treatment (P < 0.05). CONCLUSIONS: Treatment with the Rho/ROCK pathway inhibitor fasudil attenuated HG-induced monocyte-endothelial cell adhesion, possibly by reducing endothelial expression of VCAM-1 and MCP-1. These results suggest inhibition of Rho/ROCK signaling may have therapeutic potential in preventing diabetes associated vascular inflammation and atherogenesis.
format Online
Article
Text
id pubmed-3461463
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34614632012-10-02 ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion Li, Hailing Peng, Wenhui Jian, Weixia Li, Yuanmin Li, Qi Li, Weiming Xu, Yawei Cardiovasc Diabetol Original Investigation BACKGROUND: Previous studies suggested that the RhoA/ROCK pathway may contribute to vascular complications in diabetes. The present study was designed to investigate whether ROCK inhibitor fasudil could prevent high glucose-induced monocyte-endothelial cells adhesion, and whether this was related to fasudil effects on vascular endothelial cell expression of chemotactic factors, vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1). METHODS: HUVECs were stimulated with high glucose (HG) or HG + fasudil in different concentration or different time. Monocyte-endothelial cell adhesion was determined using fluorescence-labeled monocytes. The mRNA and protein expression of VCAM-1 and MCP-1 were measured using real-time PCR and western blot. The protein levels of RhoA, ROCKI and p-MYPT were determined using western blot analysis. ELISA was employed to measure the expression of soluble VCAM-1 and MCP-1 in cell supernatants and human serum samples. RESULTS: Fasudil significantly suppressed HG-induced adhesion of THP-1 to HUVECs. Fasudil reduced Rho/ROCK activity (as indicated by lower p-MYPT/MYPT ratio), and prevented HG induced increases in VCAM-1 and MCP-1 mRNA and protein levels. Fasudil also decreased MCP-1 concentration in HUVEC supernatants, but increased sVCAM-1 shedding into the media. In human diabetic subjects, 2 weeks of fasudil treatment significantly decreased serum MCP-1 level from 27.9 ± 10.6 pg/ml to 13.8 ± 7.0 pg/ml (P < 0.05), while sVCAM-1 increased from 23.2 ± 7.5 ng/ml to 39.7 ± 5.6 ng/ml after fasudil treatment (P < 0.05). CONCLUSIONS: Treatment with the Rho/ROCK pathway inhibitor fasudil attenuated HG-induced monocyte-endothelial cell adhesion, possibly by reducing endothelial expression of VCAM-1 and MCP-1. These results suggest inhibition of Rho/ROCK signaling may have therapeutic potential in preventing diabetes associated vascular inflammation and atherogenesis. BioMed Central 2012-06-13 /pmc/articles/PMC3461463/ /pubmed/22694757 http://dx.doi.org/10.1186/1475-2840-11-65 Text en Copyright ©2012 Li et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Li, Hailing
Peng, Wenhui
Jian, Weixia
Li, Yuanmin
Li, Qi
Li, Weiming
Xu, Yawei
ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion
title ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion
title_full ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion
title_fullStr ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion
title_full_unstemmed ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion
title_short ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion
title_sort rock inhibitor fasudil attenuated high glucose-induced mcp-1 and vcam-1 expression and monocyte-endothelial cell adhesion
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461463/
https://www.ncbi.nlm.nih.gov/pubmed/22694757
http://dx.doi.org/10.1186/1475-2840-11-65
work_keys_str_mv AT lihailing rockinhibitorfasudilattenuatedhighglucoseinducedmcp1andvcam1expressionandmonocyteendothelialcelladhesion
AT pengwenhui rockinhibitorfasudilattenuatedhighglucoseinducedmcp1andvcam1expressionandmonocyteendothelialcelladhesion
AT jianweixia rockinhibitorfasudilattenuatedhighglucoseinducedmcp1andvcam1expressionandmonocyteendothelialcelladhesion
AT liyuanmin rockinhibitorfasudilattenuatedhighglucoseinducedmcp1andvcam1expressionandmonocyteendothelialcelladhesion
AT liqi rockinhibitorfasudilattenuatedhighglucoseinducedmcp1andvcam1expressionandmonocyteendothelialcelladhesion
AT liweiming rockinhibitorfasudilattenuatedhighglucoseinducedmcp1andvcam1expressionandmonocyteendothelialcelladhesion
AT xuyawei rockinhibitorfasudilattenuatedhighglucoseinducedmcp1andvcam1expressionandmonocyteendothelialcelladhesion